EUCTR2010-018295-24-IT进行中（未招募）不适用
A Phase 2b Study of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 1 and 4 Infection - ND
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 625
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Signed Written Informed Consent 2) Target Population a) Subjects chronically infected with HCV genotype 1 or 4 (genotype 4 will be capped at 10% of the randomized study population), as documented by both positive HCV RNA and anti-HCV antibody at the time of screening, and positive HCV RNA, anti-HCV antibody, or HCV genotype test at least 6 months prior to screening; b) HCV RNA viral load of = 105 IU/mL (100,000 IU/mL) at screening; c) No previous exposure to interferon, pegIFNa, or RBV; d) Results of a liver biopsy demonstrating the presence or absence of cirrhosis. Compensated cirrhotics (based on clinical criteria) with HCV genotype 1 infection are eligible, but will be capped at 10% of the randomized study population. For eligible compensated cirrhotic subjects, biopsy documenting cirrhosis can be from any time period prior to randomization. For eligible non-cirrhotic subjects, liver biopsy results must be obtained = 24 months prior to randomization; e) Ultrasound (U/S), computed tomography (CT) scan, or magnetic resonance imaging (MRI) results 12 months prior to randomization that do not demonstrate evidence of HCC; f) Body Mass Index (BMI) of 18 to 35 kg/m?, inclusive. BMI = weight (kg)/[height (m)]? at screening. 3) Age and Reproductive Status a) Men or women, 18 - 70 years of age b) Men and women of childbearing potential (WOCBP) must be using 2 separate methods of contraception to avoid pregnancy throughout the study and for up to 24 weeks after the last dose of RBV (or time specified by the country specific RBV label, whichever is longer) in such a manner that the risk of pregnancy is minimized; see Protocol Section 3.3.3 for the definition of WOCBP. c) Women must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of investigational product. Female subjects must agree to the pregnancy testing requirements in this protocol. d) Women must not be breastfeeding. e) Requirements for male subjects (based on RBV label) For further inclusion criteria, see protocol
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Target Disease Exceptions a) Infected with HCV genotypes other than 1 or 4; b) Positive HBsAg, or HIV-1/HIV-2 antibody at screening. 2) Medical History and Concurrent Diseases a) Evidence of a medical condition associated with chronic liver disease other than HCV (such as but not limited to: hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, and toxin exposure); b) Evidence of decompensated cirrhosis based on radiologic criteria or biopsy results and clinical criteria; c) HCV genotype 4 subjects with compensated cirrhosis; d) Current or known history of cancer within 5 years prior to enrollment (exceptions to this criteria are in situ carcinoma of the cervix or adequately controlled non-melanoma skin cancers); e) Any gastrointestinal disease or surgical procedure that may impact the absorption of study drug; f) Any other medical, psychiatric and/or social reason including active substance abuse or alcohol abuse as defined by Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV), Diagnostic Criteria for Drug and Alcohol Abuse (Appendix 1) which in the opinion of the investigator, would make the candidate inappropriate for participation in this study; g) Inability to tolerate oral medication; h) Poor venous access. 3) Physical and Laboratory Test Findings a) Confirmed ALT = 5 x ULN; b) Confirmed total bilirubin = 34 µmol/L (or = 2 mg/dL); c) Confirmed INR = 1.7; d) Confirmed albumin = 3.5 g/dL (35 g/L); e) Confirmed platelets = 90 x 10 billion cells/L; f) Confirmed ANC = 1.5 x 10 billion cells/L; g) Confirmed hemoglobin = 12 g/dL (120 g/L) for women and = 13 g/dL (130 g/L) for men; h) Confirmed creatinine clearance (CrCl) (as estimated by Cockcroft and Gault) = 50 mL/min; i) Patients with a screening QTcF > 450 msec (males) or > 470 msec (females), based on the average of 3 or more ECGs (ECGs obtained 5 minutes apart while subject is resting in a supine position). 4) Medical History or Laboratory Findings that Exclude Subjects from Peg-Interferon Alfa-2a or Ribavirin Therapy The following exclusion criteria are based on guidelines or recommendations from the pegIFNa-2a and RBV package inserts: a) Severe psychiatric disease, especially untreated or unstable depression, that would prohibit used of pegIFNa-2a as judged by the investigator; b) History of hemoglobinopathies (ie, thalassemia major or sickle cell anemia), diagnoses associated with an increased baseline risk for anemia (eg, spherocytosis), hemolytic anemia, or disease in which anemia would be medically problematic; c) History of thyroid dysfunction not adequately controlled or screening thyroid function tests that indicate abnormal thyroid function; d) History of chronic pulmonary disease associated with functional limitation; e) Unstable or clinically significant cardiovascular disease or hypertension that could be expected to progress, recur or change during study period to such an extent that it could bias the assessment of the clinical status of the patient; For further exclusion criteria, see protocol.
研究者
相似试验
进行中（未招募）
不适用
Study of BMS-790052 Add-On to Standard of Care in Treatment Naive SubjectsChronic Hepatitis CMedDRA version: 14.0Level: LLTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2010-018295-24-DKBristol Myers Squibb International Corporation625
进行中（未招募）
不适用
Study of BMS-790052 Add-On to Standard of Care in Treatment NaiveSubjectsEUCTR2010-018295-24-SEBristol-Myers Squibb International Corporation625
进行中（未招募）
不适用
Study of BMS-790052 Add-On to Standard of Care in Treatment NaiveSubjectsChronic Hepatitis CMedDRA version: 14.0Level: LLTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2010-018295-24-DEBristol-Myers Squibb International Corporation625
进行中（未招募）
1 期
A Phase 2b Study of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 1 and 4 InfectioEUCTR2010-018295-24-FRBristol-Myers Squibb International Corporation625
进行中（未招募）
不适用
A Phase 2B Study of BMS-790052 in Combination with Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Infected Subjects Who are Null or Partial Responders to Prior Treatment with Peginterferon Alfa plus Ribavirin Therapy - NDChronic Hepatitis CMedDRA version: 9.1Level: LLTClassification code 10008912EUCTR2010-019378-34-ITBristol-Myers Squibb International Corporation625